| Company/Division name | Impulse Biomed |
| Parent company | Impulse Biomedical |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2026 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | South Africa |
| State(s) reshored to: | MD |
| If relevant, work nearshored to: | - |
| Industry(ies): | Medical Equipment & Supplies |
| Product(s) reshored | asthma inhalers |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Infrastructure, Proximity to customers/market |
